INTRODUCTION
============

Obesity is a disease that is becoming a global issue. Obesity increases the risk of mortality and morbidity, because it is accompanied by hypertension, heart disease, type 2 diabetes, and some types of cancer ([@b1-bmb-50-566]). Pharmacotherapeutic drugs have been developed and used for treating obesity. According to meta-analysis about effects of anti-obesity drugs approved by the Food and Drug Administration (FDA), anti-obesity drugs promote moderate weight loss ([@b2-bmb-50-566]). Initially, the thyroid hormone was selected as a therapeutic target, and Amphetamine became popular for an appetite suppressant in the late 1930s ([@b3-bmb-50-566]). Sibutramine was approved for long-term treatment in 1997. Orlistat was approved by the FDA for long-term treatment in 1999. It reduces intestinal fat absorption by inhibiting gastric and pancreatic lipases that hydrolyze triglyceride. The latest approved anti-obesity drugs were liraglutide and bupropion-naltrexone in 2014 ([@b3-bmb-50-566]).

The Endocrine Society suggests use of approved anti-obesity drugs to preserve long-term weight improves complications of obesity and increases adaptation to behavioral modification ([@b4-bmb-50-566]). However, safety concerns for anti-obesity drugs have emerged, and some drugs have been removed from the market. For example, dexfenfluramine, associated with cardiovascular side effects was withdrawn from FDA approval in 1997. Sibutramine also provokes severe cardiovascular events ([@b5-bmb-50-566]). Moreover, even with current drugs on the market such as orlistat, bupropion-naltrexone, phentermine-topiramate and liraglutide, treatment decisions are driven by co-existing medical conditions ([@b6-bmb-50-566]). For example, liraglutide may be a more relevant agent in individuals with type 2 diabetes because it lowers blood glucose levels. The use of bupropion-naltrexone in patients with alcohol or opioid dependence is associated with neuropsychiatric complications ([@b7-bmb-50-566]). Finally, the U.S. Drug Enforcement Administration (DEA) has classified most anti-obesity drugs as controlled substances, and many states have passed strict regulations relative to prescriptions and use.

Even if only 5 percent of weight is lost, the risk of metabolic disorders such as type 2 diabetes, non-alcoholic fatty liver disease or hypertension is significantly reduced ([@b8-bmb-50-566]). The goal of anti-obesity drugs is to enable weight loss of more patients. A barrier to drug approval is not only individuals with health risks but also healthy individuals that may use anti-obesity drugs which may lead to serious side effects. Low side-effects from drugs are essential for approval ([@b1-bmb-50-566], [@b9-bmb-50-566], [@b10-bmb-50-566]).

Consequently, the primary objective of our research was to identify anti-obesity drugs by screening natural products, without significant side effects. We used a library using in clinic with other purpose to cure diseases, such as antibiotics and anti-cancer agents. We established a screening method to determine lipid accumulation using 3T3-L1 cells. After screening with natural products, we identified kahweol, that is a diterpene found in beans of *Coffea arabica* and structurally related to cafestol ([Fig. 1A and B](#f1-bmb-50-566){ref-type="fig"}). Recent research suggests that kahweol may have beneficial effects on bones by inhibiting osteoclast differentiation ([@b11-bmb-50-566]). Another recent study revealed that kahweol has anti-inflammatory and anti-angiogenic effects ([@b12-bmb-50-566]), offering a possible mechanism for epidemiological studies revealing a relationship between unfiltered coffee intake and decreased risk of cancer.

In this study, we examined kahweol's effect on adipocyte differentiation and lipid accumulation. Because AMP-Activated Protein Kinase (AMPK) is an enzyme regulating glucose transport and lipid metabolism, AMPK is a therapeutic target of diabetic agent anti-and obesity ([@b13-bmb-50-566]). Interestingly, we determined that kahweol has a potent effect on activation of AMPK, thereby increasing glucose uptake in blood of sugar-taken mice. We suggest that kahweol may be an ideal agent for obesity attenuation and suggest clinical trials further examine potential applications.

RESULTS
=======

Kahweol reduces lipid accumulation in 3T3-L1 cells
--------------------------------------------------

Excessive increase of adipocyte number (hyperplasia) and adipocyte size (hypertrophy) contributes to obesity. In adults, obesity is caused by an increase in adipocyte size in white adipose tissue from excessive storage of triglyceride. Inhibition of triglyceride accumulation in adipocytes is a promising strategy for prevention and treatment of obesity. To not influence mitotic clonal expansion, a period when cells proliferate during adipocyte differentiation, 3T3-L1 cells were treated with different concentration of kahweol 2 days after MDI-induction. Lipid accumulation in 3T3-L1 cells was measured using Oil Red O staining on day 6 ([Fig. 1C](#f1-bmb-50-566){ref-type="fig"}). Kahweol (25 μg/ml) significantly reduced lipid accumulation, whereas cafestol did not reduce lipid accumulation ([Figs. 1C and D](#f1-bmb-50-566){ref-type="fig"}). To confirm the inhibitory effect of kahweol on lipid accumulation is not a result of cell cytotoxicity, a cell viability assay was conducted. We confirmed there was no difference in cell viability ([Fig. 1E](#f1-bmb-50-566){ref-type="fig"}). We tested if kahweol treatment affects protein expression of PPARγ, C/EBPα, FABP4, and FASN, that regulate adipocyte differentiation and lipid metabolism. Kahweol significantly reduced expression of these proteins in a dose-dependent manner ([Fig. 1F](#f1-bmb-50-566){ref-type="fig"}).

Kahweol suppresses the expression of adipogenesis and lipid accumulation-related genes in 3T3-L1 cells
------------------------------------------------------------------------------------------------------

We identified that 25 μg/ml kahweol has an inhibitory effect on lipid accumulation through dose-dependent treatment ([Fig. 2A](#f2-bmb-50-566){ref-type="fig"}). To examine how kahweol treatment affects adipogenesis and lipid accumulation-related genes during adipocyte differentiation, cell lysates were prepared on days 0, 2, 4, and 6. We treated cells with kahweol 2 days after adipogenic stimuli, focusing on the effect of kahweol on lipid accumulation. Kahweol significantly repressed mRNA ([Fig. 2B](#f2-bmb-50-566){ref-type="fig"}) and protein expression ([Fig. 2C](#f2-bmb-50-566){ref-type="fig"}) of PPARγ, C/EBPα, FABP4, and FASN after 2 days of treatment, suggesting that kahweol affects adipogenesis and lipid accumulation.

Kahweol reduces MDI-induced adipocyte differentiation and lipid droplet size
----------------------------------------------------------------------------

To demonstrate the effect of kahweol on MDI-induced adipogenesis, 3T3-L1 cells were treated with MDI and kahweol at day 0. Kahweol treatment reduced adipocyte differentiation and lipid accumulation ([Fig. 3A](#f3-bmb-50-566){ref-type="fig"}). We also examined the effect of kahweol on late adipocyte differentiation. 3T3-L1 cells were incubated with kahweol from days 6 to 10. Kahweol treatment slightly reduced lipid accumulation, and we revealed lipid droplet size in kahweol-treated 3T3-L1 cells was smaller than that of control cells ([Fig. 3B](#f3-bmb-50-566){ref-type="fig"}).

To identify kahweol's effect on MDI-induced mitotic clonal expansion, we measured cell number on day 0 and 2. On day 2, vehicle-treated 3T3-L1 cell number increased about 1.8-fold compared with that in day 0. Kahweol-treated 3T3-L1 cell number also increased, compared with that at day 0, but increased significantly less than vehicle-treated samples ([Fig. 3C](#f3-bmb-50-566){ref-type="fig"}). Data indicate that kahweol represses adipocyte differentiation through inhibition of mitotic clonal expansion and reduces lipid droplet size.

Kahweol inhibits lipid accumulation and increase glucose uptake through activation of AMPK
------------------------------------------------------------------------------------------

Many studies have reported that kahweol suppresses activation of AKT and ERK1/2 ([@b11-bmb-50-566], [@b14-bmb-50-566]). AKT and ERK1/2 pathways were reported to regulate adipocyte maturation ([@b15-bmb-50-566]). We examined changes in activation of these signaling pathways that are involved in adipocyte differentiation and lipid metabolism ([Fig. 4A](#f4-bmb-50-566){ref-type="fig"}). Phosphorylation of AKT and JAK2 decreased after kahweol treatment; in contrast, phosphorylation of ERK1/2 was not affected by kahweol treatment. Interestingly, we found that kahweol treatment significantly increased the phosphorylation of AMPK and its downstream target Acetyl-CoA carboxylase (ACC). We also validated that kahweol treatment increased phosphorylated AMPK and ACC in a time-dependent manner ([Fig. 4B](#f4-bmb-50-566){ref-type="fig"}). Many studies have reported that AMPK is activated by phosphorylation and that it inhibits adipocyte differentiation and increases glucose uptake and fatty acid oxidation ([@b13-bmb-50-566]).

We investigated if kahweol may inhibit lipid accumulation through AMPK activation. The inhibitory effect of kahweol on lipid accumulation was alleviated by knockdown of AMPK using siRNAs ([Fig. 4C](#f4-bmb-50-566){ref-type="fig"}). Knockdown of AMPK also reduced the effect of kahweol on expression of adipogenesis and lipid metabolism-related genes ([Fig. 4D](#f4-bmb-50-566){ref-type="fig"}). These results suggest that kahweol suppresses lipid accumulation by up-regulation of AMPK activation. Activation of AMPK promotes cellular glucose uptake through glucose transporter. Metformin known as AMPK activator has an anti-diabetic effect ([@b16-bmb-50-566]). Since kahweol also has the effect of AMPK activation as metformin, we hypothesized that kahweol may reveal an anti-diabetic effect. In 3T3-L1 cells, kahweol treatment elevated glucose uptake in a dose-dependent manner ([Fig. 4E](#f4-bmb-50-566){ref-type="fig"}). In addition, we tested if kahweol may improve glucose homeostasis in vivo. 8 week-old mice were administered kahweol every 2 days by oral gavage. After 2 weeks, we conducted glucose tolerance test (GTT). Clearance of blood glucose was faster in kahweol-treated mice than in control mice ([Fig. 4F](#f4-bmb-50-566){ref-type="fig"}).

DISCUSSION
==========

Coffee, one of the most consumed beverages globally contains a variety of ingredients that are beneficial to health. Epidemiological studies suggest that coffee consumption may reduce incidence of several chronic diseases such as obesity, type 2 diabetes, neurodegenerative diseases, Parkinson's disease, and cardiovascular diseases ([@b17-bmb-50-566]--[@b19-bmb-50-566]). Many studies have revealed that coffee consumption decreases accumulation of lipid and collagen in the liver and modulates antioxidant and inflammatory responses. However, mechanisms for its beneficial effects are not fully understood. Coffee intake is known to increase cholesterol and the diterpenes cafestol and kahweol are implicated in its effect ([@b20-bmb-50-566]). Cafestol and kahweol cause extracellular accumulation of LDL by reducing activity of hepatic LDL receptors ([@b21-bmb-50-566]).

In this study, we determined the molecular mechanism by which kahweol inhibits lipid accumulation in 3T3-L1 cells. First, we established a screening method using adipogenesis of 3T3-L1 cells. We treated cells with selected compounds from natural compound libraries 2 days after initiation of adipocyte differentiation, then quantified lipid accumulation in adipogenic 3T3-L1 cells by Oil Red staining. Among these compounds, we found that kahweol, a coffee-specific diterpene, has a strong anti-lipogenic effect compared to its structural analog cafestol. Kahweol inhibited lipid accumulation and adipocyte differentiation, but cafestol had no effect on these in 3T3-L1 cells. Many studies on kahweol have defined its inhibitory effects on cancer, angiogenesis, and inflammation. For example, kahweol inhibits cell growth by inducing proteasomal degradation of cyclin D1 via ERK1/2, JNK, and GKS3β-dependent phosphorylation ([@b22-bmb-50-566]) and HSP 70 Expression ([@b23-bmb-50-566]) in human colorectal cancer. Kahweol induces apoptosis via inhibition of STAT3 phosphorylation in human lung adenocarcinoma A549 cells ([@b24-bmb-50-566]). The anti-angiogenic effect of kahweol on endothelial cells was demonstrated by inhibition of MMP-2 and uPA expression ([@b12-bmb-50-566]) and inhibition of VEGFR2 signaling pathway ([@b25-bmb-50-566]). We detected that kahweol treatment reduced the expression of adipogenic factors, such as PPARγ and C/EBPα, that induce adipogenic differentiation, lipid synthesis related factor, FASN, and the lipid accumulation promoting factor FABP4.

Interestingly, we determined that kahweol induces activation of AMPK. AMPK is a serine/threonine kinase, that is a key enzyme for maintaining cellular energy homeostasis ([@b13-bmb-50-566], [@b26-bmb-50-566]). AMPK has a heterotrimer complex consisting α, β and γ subunits. Catalytic α subunit contains Thr172 phosphorylated by AMPK upstream kinase. Regulatory γ subunit has four Cystathionine β synthase (CBS) domains that create two AMP binding sites known as the Bateman domain. One of major roles of AMPK is the regulation of lipid metabolism. AMPK activation phosphorylates and inactivates acetyl-CoA carboxylase, an enzyme involved in fatty acid synthesis, and consequently inhibits synthesis of fatty acid and increases β-oxidation. AMPK also regulates glucose metabolism. AMPK increases glycolysis by activating of 6-phosphofructo-2-kinase/fructose-2, 6-bisphosphatase 2/3 and suppresses glycogen synthesis through inhibition of glycogen synthase ([@b13-bmb-50-566]). AMPK increases glucose uptake by promoting glucose transporter 4 and hexokinase 2 expressions in skeletal muscle cells ([@b27-bmb-50-566], [@b28-bmb-50-566]). AMPK modulates various metabolic processes and its dysregulation is commonly observed in type 2 diabetes, obesity, and several types of cancer. AMPK activation is a promising therapeutic strategy for alleviating metabolic dysfunction. Many studies have revealed that AMPK activators inhibit adipocyte differentiation *in vitro* and ameliorate adiposity in high-fat diet-fed obese mice ([@b29-bmb-50-566]--[@b31-bmb-50-566]). Metformin, a typical AMPK activator is an anti-diabetic drug for therapy of type 2 diabetes ([@b16-bmb-50-566]).

In this study, kahweol induces phosphorylation of AMPK. The effect of kahweol treatment on reducing lipid accumulation was decreased by depletion of AMPK, suggesting that the inhibitory effect of kahweol on lipid accumulation was due to phosphorylation of AMPK. Mice were fasted for 15 hours and then fed glucose. The blood glucose level of kahweol-pretreated mice decreased faster than untreated mice. However, we do not know how kahweol increases phosphorylation of AMPK. Thr172 phosphorylation of the AMPK α-subunit is regulated by three phosphatases: Mg^2+^/Mn^2+^ dependent protein phosphatase 1E (PPM1E), protein phosphatase 2A (PP2A), and protein phosphatase 2C (PP2C) ([@b13-bmb-50-566], [@b32-bmb-50-566]). If AMP/ATP and ADP/ATP ratios are low, phosphatases access and dephosphorylate Thr172 of AMPK α-subunit. Thr172 phosphorylation of the AMPK α-subunit is also regulated by three upstream AMPK kinases: liver kinase B1 (LKB1), calcium/calmodulin-dependent kinase 2 (CaMKK2) ([@b33-bmb-50-566]), and TGFβ-activated kinase 1 (TAK1) ([@b34-bmb-50-566]). When intracellular energy is low, level of AMP and ADP elevates and, AMP and ADP bind to Bateman domains of the AMPK γ-subunit. This leads to conformational change that exposes the catalytic domain of AMPK α-subunit, and prevents access to phosphatases. Residue Thr172 in catalytic domain of AMPK α-subunit is phosphorylated by upstream AMPK kinases. AMPK activation is regulated allosterically by competitive binding of ATP and AMP or ADP. Currently, we are studying how kahweol regulates phosphorylation of AMPK by examining AMPK-related signaling pathways and/or the kinases that are regulated by kahweol.

Together, we suggest that kahweol has anti-obesity effects and should be studied further for possible therapeutic applications.

MATERIALS AND METHODS
=====================

Materials and methods are available in [supplementary information](#s1-bmb-50-566){ref-type="supplementary-material"}.
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![Kahweol inhibits lipid accumulation in 3T3-L1 cells, whereas cafestol has no effect on lipid accumulation. (A) Structure of kahweol. (B) Structure of cafestol. (C, D) Oil Red O staining of kahweol- and cafestol-treated 3T3-L1 cells. After MDI induction, 3T3-L1 cells were treated with kahweol or cafestol on days 2--6. Oil Red O staining was performed on day 6. Measurement of lipid accumulation. Stained ORO was eluted with 100 percent isopropanol and measured using the OD500. \*\*\*P \< 0.001, DMSO vs. kahweol, DMSO vs. cafestol. (E) Cell viability assays. Confluent 3T3-L1 cells were treated with kahweol for 48 hours. (F) Protein expression of PPARγ, C/EBPα, FABP4, and FASN was detected by western blotting. Protein expression was normalized to β-actin.](bmb-50-566f1){#f1-bmb-50-566}

![Kahweol attenuates expression of adipogenic factors. (A) Oil Red O staining of kahweol-treated 3T3-L1 cells. After MDI induction, 3T3-L1 cells were treated with kahweol on days 2--6. Oil Red O staining was conducted on day 6. (B) mRNA expression of PPARγ, C/EBPα, FABP4, and FASN was detected by real-time PCR. RNA samples were prepared on days 0, 2, 4, and 6. 3T3-L1 cells were treated with kahweol on days 2--6. mRNA expression was normalized to β-actin. \*\*\*P \< 0.001, DMSO vs. kahweol. (C) Protein expression of PPARγ, C/EBPα, FABP4, and FASN was detected by western blotting. Protein samples were prepared on days 0, 2, 4, and 6. 3T3-L1 cells were treated with kahweol on days 2--6. Protein expression was normalized to β-actin.](bmb-50-566f2){#f2-bmb-50-566}

![Kahweol inhibits mitotic clonal expansion and reduces lipid droplet size. (A) Oil Red O staining and lipid accumulation of kahweol-treated 3T3-L1 cells. 3T3-L1 cells were treated with MDI and kahweol for day 2. Oil Red O staining was conducted on day 6. (B) Oil Red O staining and lipid accumulation of kahweol-treated 3T3-L1 cells. 3T3-L1 cells were treated with kahweol on days 6--10. Oil Red O staining was conducted on day 10. (C) Increase of cell numbers during mitotic clonal expansion. 3T3-L1 cells were treated with DMI and kahweol until day 2, and cell numbers were measured on day 0 and 2. \*P \< 0.05, \*\*P \< 0.01, \*\*\*P \< 0.001, untreated control vs. kahweol.](bmb-50-566f3){#f3-bmb-50-566}

![Kahweol reduces lipid accumulation and increase glucose uptake through activation of AMPK. (A) Western blot analysis of signal transduction-related proteins. 3T3-L1 cells were treated with kahweol on day 2 and incubated for 24 hours. (B) Activity of signal transduction-related proteins, such as AMPK and ACC was detected by western blotting. 3T3-L1 cells were treated with kahweol on day 2. (C) Knockdown of AMPKa1 using small interfering RNA (siRNA). After transfection of AMPKa1 siRNA, 3T3-L1 cells were incubated with MDI. Then, 3T3-L1 cells were treated with kahweol on day 2. \*\*\*P \< 0.001, scRNA vs. siAMPK. (D) Protein expression of PPARγ and C/EBPα was detected by western blotting. Protein samples were prepared on day 4. (E) Glucose uptake analysis. 3T3-L1 cells were incubated with kahweol or metformin for 48 hours. The remaining level of glucose in media was measured using a glucose assay kit. Metformin was used as a positive control. \*P \< 0.05, \*\*P \< 0.01, \*\*\*P \< 0.001, untreated control vs. kahweol, untreated control vs. metformin (F) Glucose tolerance test (n = 5 for each group). 8 week-old C57BL/6 mice were treated with the vehicle (DMSO) or kahweol (100 mg/kg) every 2 days via oral administration. After 2 weeks, the glucose tolerance test was conducted at 0, 15, 30, 60, 90, and 120 minutes. \*P \< 0.05, vehicle (n = 5) vs. kahweol (n = 5).](bmb-50-566f4){#f4-bmb-50-566}
